Pidnarulex is under clinical development by Senhwa Biosciences and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pidnarulex’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pidnarulex Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pidnarulex overview

Pidnarulex is under development for the treatment of relapsed/refractory haematological malignancies including non-Hodgkin lymphoma, acute myeloid leukemia, multiple myeloma, triple negative breast cancer, advanced castration-resistant prostate cancer, chemotherapy resistant epithelial ovarian cancer, pancreatic cancer, ovarian cancer, peritoneal cancer, fallopian tube cancer, prostate cancer, breast cancer, pediatric neuroblastoma and other cancers. It is administered through intravenous route. The drug candidate targets RNA polymerase I and topoisomerase II beta. It is a G4-stabilizing compound. The drug candidate is developed based on synthetic lethality technology.

Senhwa Biosciences overview

Senhwa Biosciences (Senhwa) is a clinical-stage drug development company. The company develops next-generation DNA damage response drugs for the treatment of cancer. Its pipeline products include CX-5461 and CX-4945. Its CX-5461 product is used for the treatment of breast cancer, ovarian cancer or solid tumors and hematological malignancies. The company’s other product candidate CX-4945 is used for the treatment of prostate cancer, cholangiocarcinoma, basal cell carcinoma, medulloblastoma and COVID-19. It collaborates with global investigators and service providers to develop its pipeline products. The company has operations in Taiwan and the US. Senhwa is headquartered in New Taipei City, Taipei, Taiwan.

Quick View Pidnarulex LOA Data

Report Segments
  • Innovator
Drug Name
  • Pidnarulex
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.